FDA Rejection of MDMA-Assisted Therapy Triggers Industry-Wide Reset for Psychedelic Medicine
Lykos Therapeutics slashes workforce by 75% after Complete Response Letter reveals FDA concerns about trial design and durability, forcing psychedelic research firms to reconsider regulatory strategy.
April 14, 20267 min read